NCT03642340View on ClinicalTrials.gov

A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo

UnknownOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

May 14, 2023

Study Completion Date

August 15, 2023

Conditions
Chronic Hepatitis b
Trial Locations (1)

03722

RECRUITING

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

IlDong Pharmaceutical Co Ltd

INDUSTRY

NCT03642340 - A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo | Biotech Hunter | Biotech Hunter